Feeder Cattle Hedge Lifting Strategies for North Dakota

Marketing,

Probing Split Supersymmetry with Cosmic Rays

A striking aspect of the recently proposed split supersymmetry is the existence of heavy gluinos which are metastable because of the very heavy squarks which mediate their decay. In this paper we correlate the expected flux of these particles with the accompanying neutrino flux produced in inelastic $pp$ collisions in distant astrophysical sources. We show that an event rate at the Pierre Auger Observatory of approximately 1 yr$^{-1}$ for gluino masses of about 500 GeV is consistent with existing limits on neutrino fluxes. The extremely low inelasticity of the gluino-containing hadrons in their collisions with the air molecules makes possible a distinct characterization of the showers induced in the atmosphere. Should such anomalous events be observed, we show that their cosmogenic origin, in concert with the requirement that they reach the Earth before decay, leads to a lower bound on their proper lifetime of the order of 100 years, and consequently, to a lower bound on the scale of supersymmetry breaking, $\Lambda_{\rm SUSY} >2.6 \times 10^{11}$ GeV. Obtaining such a bound is not possible in collider experiments.Comment: Version to be published in Phys. Rev.

Effectiveness of the spot-on combination of moxidectin and imidacloprid (Advocate®) in the treatment of ocular thelaziosis by Thelazia callipaeda in naturally infected cats

Background: The present study evaluated the therapeutic effectiveness of moxidectin 1.0% (w/v) and imidacloprid 10% (w/v) (Advocate® spot-on solution for cats, Bayer Animal Health) against natural infections with the eyeworm Thelazia callipaeda in cats. This study was conducted as a GCP, negative-controlled, blinded and randomised field study in privately owned cats living in an area in southern Italy where T. callipaeda is enzootic. Methods: The study was carried out in 30 cats (19 females and 11 males, aged from 8 months to 5 years, weighing 1.2-5.2 kg) of different breeds, naturally infected by T. callipaeda. At study inclusion (Day 0), animals were physically examined and the infection level was assessed by examination of both eyes for clinical score and live adult T. callipaeda count. Each cat was weighed and randomly assigned to one of the treatment groups (G1: Advocate, G2: untreated control). Clinical assessments and T. callipaeda adult counts were performed on Day 14. At the study completion visit on Day 28, clinical assessments and counts of T. callipaeda adults and larvae were performed. All cats were daily observed by their owners and general health conditions were recorded during the entire period of the study. Results: The primary effectiveness variable was the percentage of animals in G1 group (Advocate) showing a complete elimination (parasitological cure) of adult eye worms at Day 14 and Day 28. The effectiveness of the treatment in the G1 group was 93.3 and 100% at Day 14 and Day 28, respectively, when compared to group G2. Total worm count reduction from both eyes for Advocate was 96.3% on Day 14 and 100% on Day 28. Clinical data were confirmed by the examination of conjunctival pouch flushing. An overall reduction in the number of cats with lacrimation and conjunctivitis was observed following treatment despite the fact that in a few cats treated with Advocate clinical signs persisted due to the chronic nature of the disease. Conclusions: Based on the results of the present trial, a single dose of Advocate was found to be safe and highly effective in the treatment of natural T. callipaeda infection in cats